MARTIN-BLONDEL, Guillaume; MARCELIN, Anne-Geneviève; SOULIÉ, Cathia; KAISARIDI, Sofia; LUSIVIKA-NZINGA, Clovis; DORIVAL, Céline; NAILLER, Laura; BOSTON, Anaïs; MELENOTTE, Cléa; CABIÉ, André; CHOQUET, Christophe; COUSTILLÈRES, François; MARTELLOSIO, Jean-Philippe; GAUBE, Géraldine; TRINH-DUC, Albert; RONCHETTI, Anne-Marie; POURCHER, Valerie; CHAUVEAU, Marie; LACOMBE, Karine; PEIFFER-SMADJA, Nathan; HOUSSET, Pierre; PERROT, Aurore; PIALOUX, Gilles; MARTIN, Aurélie; DUBEE, Vincent; DEVAUX, Mathilde; FREY, Jérôme; CAZANAVE, Charles; LIBLAU, Roland; CARRAT, Fabrice; YORDANOV, Youri

doi:10.1016/j.jinf.2022.06.033

Langue

Article de revue

Ce document a été publié dans

Journal of Infection. 2022, vol. 85, n° 4, p. E104-E108

Résumé en anglais

Before the Omicron era, the neutralizing antibody targeting the SARS-CoV2 Spike protein Sotrovimab has been shown to reduce the risk of COVID-19-related hospitalization in patients who are at high risk for progression (1, 2). We recently showed that early administration of Sotrovimab in Omicron-infected patients with very high-risk for progression was associated with a low rate of COVID-19-related hospitalization within one month after treatment administration (3%), and with no death (1). However, the dominance of the Omicron sublineage BA.2 led health agencies to suspend Sotrovimab emergency use authorizations because of its lower neutralizing ability in vitro compared to BA.1 sublineage (3, 4). Clinical efficiency of Sotrovimab to prevent COVID-19 related complications in high-risk patients with mild-to-moderate COVID-19 Omicron BA.2 remains unknown. Our aim was to compare the clinical and virological outcomes of Omicron BA.1 and BA.2-infected patients with mild-to-moderate COVID-19 who received 500 mg of Sotrovimab IV to prevent COVID-19-related complications.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/182164

DOI

http://dx.doi.org/10.1016/j.jinf.2022.06.033

Unités de recherche

MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Sotrovimab to Prevent Severe COVID-19 in High-Risk Patients Infected with Omicron BA.2

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche